Illinois-based Baxter International and ScinoPharm Taiwan have announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments.
The generic injectable medications include treatments for lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy.
Under the terms of the partnership, Baxter and API manufacturer ScinoPharm will collaborate on product development and manufacturing. Baxter will hold commercialization rights, with products included in the arrangement expected to launch beginning in 2020. ScinoPharm will provide APIs for the initial five generic injectables, and Baxter and ScinoPharm will share manufacturing responsibilities, with the majority of the molecules to be manufactured at Baxter’s state-of-the-art facility in Halle, Germany.
Read the press release